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Aims: To compare the analgesic effect of topical benzocaine (5%) and ketoprofen (1.60 mg/mL) after 2 mm activation of 7 mm 
long delta loops used for maxillary en-masse orthodontic space closure. 
Subjects and methods: Twenty patients (seven males, 13 females, 15–25 years of age, mean age of 19.5 years) participated 
in a randomised crossover, double-blind trial. After appliance activation, participants were instructed to use analgesic gels and 
record pain perception at 2, 6, 24 hours and 2, 3 and 7 days (at 18.00 hrs), using a visual analogue scale ruler (VAS, 0–4). 
Each patient received all three gels (benzocaine, ketoprofen, and a control (placebo)) randomly, but at three different appliance 
activation visits following a wash-over gap of one month. After the first day, the patients were instructed to repeat gel application 
twice a day at 10:00 and 18:00 hrs for three days. The recorded pain scores were subjected to non-parametric analysis. 
Results: The highest pain was recorded at 2 and 6 hours. Pain scores were significantly different between the three groups 
(Kruskal–Wallis test, p < 0.01). The overall mean (SD) pain scores for the benzocaine 5%, ketoprofen, and control (placebo) 
groups were 0.89 (0.41), 0.68 (0.34), and 1.15 (0.81), respectively. The pain scores were significantly different between the 
ketoprofen and control groups (mean difference = 0.47, p = 0.005). All groups demonstrated significant differences in pain 
scores at the six different time intervals (p < 0.05) and there was no gender difference (p > 0.05). 
Conclusion: A significant pain reduction was observed following the use of ketoprofen when tested against a control gel 
(placebo). The highest pain scores were experienced in patients administered the placebo and the lowest scores in patients who 
applied ketoprofen gel. Benzocaine had an effect mid-way between ketoprofen and the placebo. The highest pain scores were 
recorded 2 hours following force application, which decreased to the lowest scores after 7 days.
(Aust Orthod J 2016; 32: 64–72)
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Introduction
Following the activation of orthodontic appliances, 
patients may experience pain and discomfort. Pain 
is the most frequent complaint of orthodontic pa-
tients1 and considered as the contributory factor 
to a patient’s refusal to accept orthodontic treat-
ment.1 Many studies have found that pain follow-
ing separator or archwire placement starts within 
four hours, continues until at least 24 hours, and 
dissipates by day seven.1-7 The disruption of the 
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periodontal tissues following the application of an 
orthodontic force leads to the initiation of a cascade 
of events involving the release of inflammatory me-
diators into the local environment8,9 and pain percep-
tion. However, the exact mechanism of pain related to 
orthodontic treatment is not clearly understood.
A number of strategies have been proposed to reduce 
orthodontic pain, including the oral administration of 
non-steroidal anti-inflammatory drugs (NSAIDs),1-7,10 
chewing gum or a bite wafer9,11-13 and topical 
anaesthesia gel application.14
Topical anaesthesia is commonly used in clinical 
dentistry to reduce the discomfort of local anaesthetic 
administration15-23 and for minor intra-oral operative 
procedures such as periodontal scaling and root 
planning,24,25 gingival manipulation,26,27 biopsy,28,29 
dentinal/pulpal anaesthesia,30 as well as extractions,31 
the reduction of patient anxiety32,33,34 or, recently, for 
the placement of orthodontic TADs.34 Benzocaine has 
also been used to relieve oral mucosal pain caused by 
orthodontic appliances.35,36 So far, other orthodontic 
pain reduction methods such as transcutaneous 
electrical nerve stimulation,37 low-level laser 
therapy38,39 and vibratory stimulation40,41 have not 
gained clinical popularity.
Although oral NSAIDs are effective in the treatment 
of acute and chronic pain conditions, their use may 
be associated with systemic side effects, particularly 
gastrointestinal disorders.7,42 In order to minimise the 
incidence of related systemic events, topical NSAIDs 
have been developed.43 Topical NSAIDs are applied 
as gels, creams or sprays that penetrate the skin, 
subcutaneous fatty tissue and muscle in amounts that 
are sufficient to exert a therapeutic effect on peripheral 
and central mechanisms in the absence of high plasma 
concentrations. Data indicate that, for instance, 
topical Ketoprofen is effective at relieving pain in a 
number of acute and chronic pain situations.43
Ketoprofen is a non-steroidal anti-inflammatory drug 
and a derivative of propionic acid which inhibits 
aspects of the prostaglandin/leukotriene pathway to 
reduce inflammatory reactions. The rapid absorption, 
short plasma half-life, and equally rapid elimination 
of ketoprofen reduce the toxic build-up of the drug.44 
The efficacy of ketoprofen has been approved for mild 
to moderate pain.43-46
A literature search revealed few studies that investi-
gated the effect of orthodontic pain.46 The use of 
benzocaine for orthodontic patients is limited to the 
assessment of pain caused by orthodontic separators 
or the use of benzocaine wax at relatively high doses 
(20%).17,23,34 Furthermore, most orthodontic studies 
have assessed pain levels at the start or after the place-
ment of orthodontic separators.1-7 The aim of this 
prospective, randomised, double-blind study with a 
crossover design was therefore to assess the pain expe-
rienced during fixed appliance treatment in a control 
group compared with patients treated with topical 
ketoprofen or benzocaine (5%) gels. The pain was 
generated by the activation of stainless steel looped 
archwires used for the retraction of anterior maxillary 
teeth or space closure as part of an orthodontic treat-
ment program.
Null hypothesis
The tested hypothesis was that there was no difference 
in the recorded orthodontic pain perceptions of a 
control group, a group treated with topical anaesthetic 




In order to detect a mean pain score difference of 1 
point between any two groups, with a standard de-
viation of 1.1,  α = 0.05, and power (1 − β) = 80%, 
Zα  = 1.96, Zβ= 0.84, an approximate sample size was 
calculated to be 30 subjects.
Study sample
After approval by the ethics committee of the Shahid 
Beheshti University of Medical Sciences, Faculty 
of Dentistry, 30 patients were enrolled in this 
randomised double-blind, crossover trial. Patients 
underwent fixed orthodontic therapy but 10 were 
ultimately excluded due to miscellaneous protocol 
violations or unwillingness to participate. Of the 
remaining 20 participants, 13 were females and 7 
were males. The age range of the patients was 15–25 
years (mean age = 19.5 years). All were at least three 
months into their fixed orthodontic treatment when 
invited to participate in the study. All patients had 
their first maxillary premolars extracted and were in 
the stage of en-masse anterior retraction with a 0.018 
× 0.025” stainless steel, looped archwire in a 0.022”–
slot edgewise system. Identical stainless steel, looped 
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archwires with a 7 mm long delta loop designed for 
the en-masse anterior retraction were prepared for 
use. The study recruitment protocol is shown in a 
CONSORT style diagram (Figure 1).47 Participants 
also met the following criteria:
•	 An absence of pain in the oral cavity (tooth or 
gingiva) at the time of inclusion in the study.
•	 No consumption of analgesics before the proce-
dure, which could potentially interfere with the 
medications.
•	 No consumption of medications with contraindi-
cations related to the drugs used.
•	 All individuals had a positive history of pain or 
discomfort after orthodontic appliance activation.
Study design and assessment of pain 
perception
The current prospective, randomised study used a 
crossover design during which each patient received 
the three gels at different time periods. By the use of 
a random number table, each patient was prescribed 
one of the three gels for the next three appointments. 
On the initial visit, informed consent was obtained 
and the patients were provided with a tube containing 
ketoprofen, benzocaine or a control (placebo) gel, 
plus a visual analogue questionnaire. After a 2 mm 
activation of the 0.018 × 0.025” looped archwire, the 
patients were instructed by a trained dental nurse on 
gel application to the gingiva (buccally and palatally) 
and the coronal aspect of the teeth and to subsequently 
complete a questionnaire. The same nurse conducted 
the crossover under the supervision of the clinician, 
who was unaware of the content of the gel tubes.
Assessment of Pain
The study questionnaire comprised a visual analogue 
scale (VAS) horizontally graded from 0–4.48 The 
patients were instructed to evaluate their orthodontic 
pain and choose an appropriate number at two, six, 
and 24 hours after archwire placement. After the 






Figure 1.  
  
Figures 1. CONSORT type diagram showing the flow of subjects through the trial.
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application of the gel twice a day at 10:00 and 18:00 
hours for three days. The pain was again recorded at 
18:00 hours on days two, three and seven using the 
VAS ruler.
At subsequent visits (two more visits with a one 
month wash-over interval), the 0.018 × 0.025” 
looped archwire was activated by a further 2 mm. 
The patients received a new tube of gel (of different 
prescription, but with the same instructions for use) 
and the VAS questionnaire. The content of the gel 
tubes provided to the patients at each appointment 
was different from those received previously and 
governed by the randomisation. The colour and 
odour of all gels were identical and the tubes were 
not labelled, to make them indistinguishable to the 
patients and clinician. The patients were advised not 
to use other pain-relieving medication apart from 
the provided gel tubes. If the pain was too severe, 
patients were given the option of leaving the study 
and employing alternative medications. Ten patients 
failed to complete the questionnaire or adhere to 
instructions and were therefore excluded from the 
investigation.
Preparation of the materials used in the 
study
The ketoprofen (1.60 mg/mL), benzocaine (5%), 
and control (placebo) gels were manufactured in 
the laboratory of the Pharmacy School of Shahid 
Beheshti University of Medical Sciences. The gels 
contained the following ingredients: Gel maker 
material of 934 (Carbomer 934P) (50 g) as the gelling 
agent, methylparaben (5 g) and propylparaben (1 g) 
as the preservatives, glycerine as a humectant (400 
mL), sodium hydroxide as the pH adjusting agent 
(pH = 6), ketoprofen (250 g) or benzocaine (200 
g), and enough ethanol as the co-solvent, as well as 
distilled water to reach the desired concentration of 
ketoprofen (1.60 mg/mL) or benzocaine (5%). As gel 
samples had an alcoholic odour due to the inclusion 
of ethanol, orange essence was added as a flavouring 
agent to mask the smell and improve the taste. After 
manufacture, the gels were filled in 90 identical tubes 
of 20 g each (30 tubes for each gel, Razak Company, 
Tehran, Iran).
Statistical analysis
The mean, standard deviation (SD) of the pain 
severity scores as well as the mean pain rank were 
measured for each gel and for all observations at 
the six time intervals. The mean pain rank (VAS 
scores) was evaluated using the nonparametric tests 
for overall differences between the three gels and for 
each gel to compare pain perception at the six time 
intervals. Similarly, the 95% confidence interval of 
mean VAS pain ranks at the six time intervals, as 
well as post-hoc test was used for paired comparisons 
between the control gel and the experimental gels. A 
p < 0.05 level was considered as statistically significant.
Results
VAS pain scores for all groups
There was no significant gender differences in the 
recorded VAS pain scores (p > 0.05). No harmful 
or unintended effects were noted. The assessment 
of recorded pain VAS scores showed statistically 
significant differences (Kruskal-Wallis, Chi-square 
= 12.684, df = 2, p = 0.002) between ketoprofen, 
benzocaine and the control (placebo) gels. The mean 
pain rank for benzocaine 5%, ketoprofen and the 
control (placebo) gels was 182.19, 157.50, and 201.8, 
respectively. The corresponding mean (SD) values 
of pain scores were 0.89 (0.41), 0.68 (0.34), and 
1.15 (0.81). The post-hoc multiple comparison tests 
indicated significant differences between ketoprofen 
and the control (placebo) gels only (mean VAS 
pain difference = 0.47, p = 0.005). Therefore, the 
null hypothesis for this study was partially rejected. 
Overall, there were statistically significant differences 
(Chi-square = 117.741, df = 5, p = 0.0001) in the 
VAS pain scores for all gels at the six time intervals 
of the experiment. The mean pain rank for two, six 
and 24 hours and two, three, and seven days were 
251.63, 236.01, 211.56, 149.44, 127.43 and 106.63, 
respectively. The mean (SD) values of the recorded 
pain scores were 1.75 (0.67), 1.55 (0.51), 1.2 (0.47), 
0.5 (0.31), 0.32 (0.21) and 0.13 (0.1) at two, six, 
and 24 hours, and on two, three and seven days, 
respectively. Overall, there was a steady reduction in 
recorded pain intensity over the seven day evaluation 
period.
The comparison between ketoprofen, 
benzocaine and control (placebo) gels
Significant differences (Chi-square = 47.638, df = 5, 
p = 0.0001) were noted in the VAS pain scores at the 
six time intervals for the group that used benzocaine 
gel. Similar findings were observed for ketoprofen 
(Chi-square = 45.623, df = 5, p = 0.0001) and the 
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control (placebo) groups (Chi-square = 39.726, df = 5, 
p = 0.0001). Table I shows the findings of the post-
hoc multiple comparisons for the three gels at the 
different time intervals.
A comparison of the pain scores for the three groups 
and six studied time periods by the Kruskal-Wallis 
test (Table II) revealed that significant differences 
were present at 24 hours (p = 0.01) and at day two (p 
= 0.04). The post-hoc tests demonstrated significant 
differences between the ketoprofen and benzocaine 
gels at 24 hours (p < 0.05) and between the ketoprofen 
and control (placebo) gel on day two (p < 0.05). No 
other statistically significant differences were noted. 
Time intervals Time intervals
Mean pain score 
diff., benzocaine p value
Mean pain score 
diff., ketoprofen p value
Mean pain score 
diff., placebo p value
2 hrs 6 hrs 0.2 1  0.25 1   0.55 0.94
2 hrs 24 hrs  0.05 1  0.95  0.18   0.64 0.71
2 hrs Day 2 1 0.03  1.35   0.004 1.4   0.003
2 hrs Day 3  1.15 0.01  1.40   0.002   1.75   0.0001
2 hrs Day 7  1.35  0.001  1.55   0.001   1.95   0.0001
6 hrs 24 hrs  0.25 1 0.7  0.62 0.1 1
6 hrs Day 2 1.2  0.002 1.1 0.03   0.85 0.27
6 hrs Day 3  1.35  0.001  1.15 0.02  1.2 0.02
6 hrs Day 7  1.55 0.0001  1.30   0.006  1.4  0.003
24 hrs Day 2  0.95 0.009 0.4 0.82   0.75 0.25
24 hrs Day 3 1.1 0.002  0.45 0.67 1.1 0.007
24 hrs Day 7 1.3 0.0001  0.60 0.18 1.3 0.001
Day 2 Day 3  0.15 1  0.05 1   0.35 0.86
Day 2 Day 7  0.35 0.32 0.2 0.86   0.55 0.18
Day 3 Day 7 0.2 0.96  0.15 0.97 0.2 0.97
Table I.  The mean difference of VAS pain scores and corresponding p values of the post-hoc multiple comparison tests for three gels at different time intervals.
Time intervals Benzocaine 5% Ketoprofen Placebo df Chi-square p value










































Mean and standard deviation of pain severity was measured for each gel at the six time intervals. The assessment of pain intensity by Kruskal-Wallis test 
indicated that statistically significant differences (p = 0.002) were found in the VAS scores among ketoprofen, benzocaine and placebo gels. Post-hoc 
multiple comparison tests (Table 1) were then utilised to explore the significant difference between paired groups, which indicated significant differences (p 
= 0.005) between ketoprofen and placebo gels.
Table II.  The mean pain ranks (95% Confidence Interval) for three gels at the six studied time intervals.
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The mean pain intensity for the three gels at the six 
studied time periods is shown in Figure 2. 
Discussion
The onset, duration, and intensity of orthodon-
tic pain were assessed in the present crossover, ran-
domised, clinical trial. Pain during orthodontic treat-
ment is known to negatively affect compliance.1,2,7,49,50 
Previous orthodontic pain studies assessed pain levels 
at the start or after the placement of orthodontic sepa-
rators1-7 as the most severe pain can be felt following 
bracket bonding and archwire attachment. The de-
sign of the present study allowed the assessment of 
the effectiveness of topical ketoprofen and benzocaine 
(5%) in reducing pain produced by the activation of 
stainless steel looped archwires, used for the retraction 
of maxillary anterior teeth. Similar to previous stud-
ies which assessed pain at the start of treatment,1-7 the 
present study noted the highest pain level in all groups 
within the first two hours of appliance activation.
It was confirmed that activation of the archwire 
without any medicament leads to discomfort and 
pain.1-3,6,7,49 It was also indicated that the application 
of ketoprofen gel led to less pain experience follow-
ing the activation of an archwire for en-masse anterior 
retraction than benzocaine 5% gel. It should be noted 
that the benzocaine concentration (5%) was consider-
ably lower than the reported figures (20%) in previ-
ous studies,17,23,34-36 but still effective in reducing the 
orthodontic pain.
The evaluation of pain at the various time intervals 
showed that the benzocaine 5% gel was an efficient 
medicament for pain suppression. However, this 
advantage did not last long and the pain intensity 
recorded at six hours co-incided with that of the 
control (placebo) group. Ketoprofen showed a 
continuous downward trend from the beginning and 
pain intensity reduced by more than 50% within 24 
hours. Benzocaine 5% showed a sharp downward 
trend after 24 hours. From the clinical perspective, 
topical anaesthetics benefit orthodontic patients 
only during the first day. The present sample was not 
equally distributed for male/female ratio and similar 
to a number of reports,35,36,39,41,51-53 gender did not 
significantly affect pain scores in the present data. 
However, two recent studies reported significant effect 
of age and sex interaction on orthodontic pain during 
adolescence, and 14-17 and 15-18-year-old girls 
experienced maximum pain. 54,55
Ketoprofen is a highly potent and safe NSAID 
derivative of the propionic acid group and was 
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Figures 2. Mean recorded VAS pain scores of the three investigated gels (control, benzocaine 5%, and ketoprofen (1.60 mg/mL)) at six studied time intervals.
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to inhibiting the formation of prostaglandins, 
ketoprofen also suppresses leukotrienes and, further, 
limits inflammation. Ketoprofen has a short half-
life, is simply metabolised, has a broad therapeutic 
window, and does not accumulate with multiple 
doses. These features contribute to a rapid onset of 
action, relatively strong analgesic properties, and 
minimal side effects.43-46,56
Most available data on ketoprofen report efficacy for 
systemic use, and ketoprofen is often prescribed for 
the relief of pain after the removal of impacted third 
molar teeth. Mehlisch et al.57 reported a decrease of 
pain scores in all studied doses of ketoprofen (25,50, 
and 100 mg) compared with codeine and a control. 
Ketoprofen administration also had a more rapid 
onset (showing no dose-related differences) and 
longer duration of action than codeine. Cooper58 
reviewed three, six-hour double-blind, single-dose, 
placebo-controlled studies in patients who had 
experienced minor dental surgery, and concluded that, 
in comparison with aspirin, significant differences 
favouring ketoprofen were found for all measures of 
analgesic efficacy. Ketoprofen appeared to have a more 
rapid onset, higher peak effect and longer duration 
of pain relief than codeine. In one study, ketoprofen 
100 mg (compared with 25 mg), had a faster onset of 
action, the highest peak effect and the longest duration 
of action over a six-hour evaluation. Therefore, it 
appeared that ketoprofen compared favourably with 
many of the commonly used NSAIDs. While the 
efficacy and rapid onset of systemic ketoprofen for 
post-operative pain has been well documented,59-61 in 
the present study, the application of ketoprofen was 
topical and not systemic.
Recently, a tendency for the local delivery of the 
analgesics has emerged.43 As an example, a solubilised 
200 mg liquigel formulation of ibuprofen (with a 
higher C
max
 and an earlier T
max
 than a tablet – C = 
concentration; T = time) has been shown to have a 
more rapid rate of absorption compared with 200 
mg tablets.61 The therapeutic effect on the nervous 
system in the absence of high plasma concentrations 
is achieved by topical NASIDs (gels, creams, or 
sprays).43 Each can penetrate the skin, subcutaneous 
fatty tissue and muscles in amounts that are sufficient 
to exert therapeutic effects.
In consideration of these characteristics and the 
required repetitive nature of analgesic administration 
in the oral cavity following orthodontic appliance 
activation, a simpler alternative to oral NSAIDs 
would be a gel form of ketoprofen applied locally. 
Lauritano et al.46 measured the pain level following the 
application of ketoprofen gel in a patient with acute 
oral inflammation due to orthodontic appliances. It 
was revealed that ketoprofen gel was more effective 
in relieving pain and controlling the inflammatory 
processes than benzidamine hydrochloride gel. The 
present study also confirmed the analgesic efficacy of 
ketoprofen over the benzocaine gel.
Unlike parallel-randomised clinical trials, crossover 
trials provide each participant with two or more 
sequential treatments in a random order separated by 
a sufficient wash-over period.62,63 Subsequently, each 
subject is able to act as his or her own control and 
permit comparisons between and within groups.63-65 
Crossover studies are popular for the investigation of 
new and developmental drugs, and most appropriate in 
studies in which the effects of the treatments are short-
lived and reversible.63,64,66  The particular strength of the 
crossover design is that the interventions are evaluated 
within the same patient, which eliminates subject 
variability.63,65 However, it is important to look for a 
carryover effect as an earlier crossover trial can affect 
the outcome at a later period and generate misleading 
placebo data. Considering the relatively short half-life 
of the materials used and the one-month wash-over 
period, it was difficult to assess a possible carryover 
effect. Regarding the ‘intention-to-treat analysis’, as the 
present sample was limited to 20, missing data due to 
patient discontinuation precluded a within-individual 
comparison for all patients enrolled in the trial.67,68 
However, it is likely that the drop-outs had a minimal 
effect on the final outcome as they were excluded 
from the outset due to the expressed unwillingness 
to participate. All 20 participants were provided and 
tested with the three gels. 
In order to demonstrate that an analgesic is working, 
it is crucial to use a placebo68 to reveal the superiority 
of the medications. However, the major concern with 
NSAIDs is the reduction in prostaglandin production 
that may interfere with orthodontic tooth movement. 
Because of this potential effect, a worthwhile extension 
of the present study would be to measure the amount 
of tooth movement and to assess whether ketoprofen 
causes a reduction. The possible interference of tooth 
movement and a correlated analgesic effect, as well 
as other potential side effects, could be a valuable 
direction for future studies.
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Conclusion
The findings of the present study indicated a significant 
decrease in pain following the use of ketoprofen when 
tested against a control (placebo) gel. The highest 
pain scores were experienced in patients administered 
the placebo gel and the lowest scores in patients who 
applied ketoprofen gel. Benzocaine had an effect mid-
way between ketoprofen and the placebo. The highest 
pain scores were recorded two hours following force 
application, which decreased to the lowest scores after 
seven days.
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